Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Dominic Schmidt
AI-generated illustration
PersonGB

Dominic Schmidt

General partner at London's Advent Life Sciences since 2022; formerly a partner at Syncona.

Last refreshed: 14 November 2026

Key Question

Can T-cell receptors crack solid tumours where antibody engagers stalled?

Timeline for Dominic Schmidt

#17 5 Nov

T-Therapeutics raises $133m in Series B

UK Startups and Innovation
View full timeline →

Background

Dominic Schmidt is a general partner at Advent Life Sciences, a London life-sciences venture investor, which appointed him in 2022. He spent eight years before that as a partner in the investment team at Syncona.

Advent co-led T-Therapeutics' $133m Series B with the British Business Bank in November 2026. Schmidt said T-cell engagers have worked in blood cancers but "have been held back in solid tumours", which he told BioPharma Dive came down to "the lack of appropriate targets". T-Therapeutics' receptors read protein fragments from inside cells, reaching targets antibodies cannot.

Advent lists his board roles as including Amphista Therapeutics, AviadoBio and Pheno Therapeutics.

Common Questions
Who is Dominic Schmidt of Advent Life Sciences?
A general partner at the London life-sciences investor, appointed in 2022 after eight years as a partner at Syncona.Source: Advent Life Sciences
Who led T-Therapeutics' Series B?
Advent Life Sciences and the British Business Bank co-led the $133m round, announced on 5 November 2026. The Bank put in £15m and took a board seat.Source: British Business Bank
Why have T-cell engagers struggled in solid tumours?
Dominic Schmidt told BioPharma Dive it came down to the lack of appropriate targets. T-cell receptors can reach targets inside cells that antibodies cannot.Source: BioPharma Dive
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.